Table 3 Correlation of HER2 expression with clinicopathological characteristics.
Parameters | HER2 immunostaining | χ2 | p | HER2 gene status | χ2 | p | ||
|---|---|---|---|---|---|---|---|---|
Moderate incomplete staining N = 117 | Intense incomplete staining N = 30 | Nonamplification N = 79 | Amplification N = 68 | |||||
Age | 0.640 | 0.424 | 0.638 | 0.424 | ||||
≤50 years | 49 (33%) | 15 (10%) | 32 (22%) | 32 (22%) | ||||
>50 years | 68 (46%) | 15 (10%) | 47 (32%) | 36 (24%) | ||||
Tumor size (cm)a | 2.093 | 0.351 | 3.324 | 0.190 | ||||
≤2 | 39 (31%) | 10 (8%) | 29 (23%) | 20 (16%) | ||||
2–5 | 56 (45%) | 11 (9%) | 38 (31%) | 29 (23%) | ||||
>5 | 5 (4%) | 3 (2%) | 2 (2%) | 6 (5%) | ||||
Histologic grade | 1.443 | 0.257 | 8.782 | 0.003 | ||||
G2 | 87 (59%) | 19 (13%) | 65 (44%) | 41 (28%) | ||||
G3 | 30 (20%) | 11 (7%) | 14 (10%) | 27 (18%) | ||||
Estrogen receptor | 27.481 | 0.000 | 26.759 | 0.000 | ||||
Positive | 108 (73%) | 16 (11%) | 78 (53%) | 46 (31%) | ||||
Negative | 9 (6%) | 14 (10%) | 1 (1%) | 22 (15%) | ||||
Progesterone receptor | 17.273 | 0.000 | 19.361 | 0.000 | ||||
Positive | 102 (69%) | 16 (11%) | 74 (50%) | 44 (30%) | ||||
Negative | 15 (10%) | 14 (10%) | 5 (3%) | 24 (16%) | ||||
Lymph-vascular invasion | 2.810 | 0.094 | 0.287 | 0.592 | ||||
Absent | 55 (37%) | 9 (6%) | 36 (24%) | 28 (19%) | ||||
Present | 62 (42%) | 21 (14%) | 43 (29%) | 40 (27%) | ||||
Lymph node statusb | 5.872 | 0.118 | 0.943 | 0.331 | ||||
Positive | 72 (55%) | 18 (14%) | 51 (39%) | 39 (30%) | ||||
Negative | 32 (24%) | 10 (8%) | 20 (15%) | 22 (17%) | ||||
AJCC stagingc | 1.141 | 0.565 | 0.671 | 0.715 | ||||
I | 16 (15%) | 2 (2%) | 12 (11%) | 6 (5%) | ||||
II | 35 (32%) | 10 (9%) | 25 (23%) | 20 (18%) | ||||
III | 39 (35%) | 8 (7%) | 27 (25%) | 20 (18%) | ||||
